当前位置：药药网 / 药品 / 美国NDC复合药物数据库文件(本栏目更新到2026-3-31)
药品名称： 商品名称： 药品NDC： 报告期内： -格式:2020-5-3
NDC包装id： 市场分类： 活性成分： 持证企业：
 美国NDC复合药物数据库文件4843条(本栏目更新到2026-3-31)
药品名称(分析)
商品名
药品NDC
专利人(分析)
报告期内
活性成分
市场分类
规格(分析)
NDC包装id
Tirzepatide
HUMAN COMPOUNDED DRUG
81483-0053
Tailstorm Health INC
2024-2
TIRZEPATIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
10 mg/.2 mL
81483-0053-4
Tirzepatide
HUMAN COMPOUNDED DRUG
81483-0052
Tailstorm Health INC
2024-2
TIRZEPATIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
7.5 mg/.3 mL
81483-0052-4
Tirzepatide
HUMAN COMPOUNDED DRUG
81483-0054
Tailstorm Health INC
2024-2
TIRZEPATIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
12.5 mg/.25 mL
81483-0054-4
Tirzepatide
HUMAN COMPOUNDED DRUG
81483-0055
Tailstorm Health INC
2024-2
TIRZEPATIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
15 mg/.3 mL
81483-0055-4
Tirzepatide
HUMAN COMPOUNDED DRUG
81483-0051
Tailstorm Health INC
2024-2
TIRZEPATIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
5 mg/.2 mL
81483-0051-4
SEMAGLUTIDE
HUMAN COMPOUNDED DRUG
81483-0049
Tailstorm Health INC
2024-2
SEMAGLUTIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
2.4 mg/.3 mL
81483-0049-4
SEMAGLUTIDE
HUMAN COMPOUNDED DRUG
81483-0048
Tailstorm Health INC
2024-2
SEMAGLUTIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
1.7 mg/.22 mL
81483-0048-4
Bevacizumab
HUMAN COMPOUNDED DRUG
81483-0041
Tailstorm Health INC
2024-2
BEVACIZUMAB
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
1.25 mg/.05 mL
81483-0041-5
SEMAGLUTIDE
HUMAN COMPOUNDED DRUG
81483-0045
Tailstorm Health INC
2024-2
SEMAGLUTIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
.25 mg/.05 mL
81483-0045-4
SEMAGLUTIDE
HUMAN COMPOUNDED DRUG
26436-5608
Hybrid Pharma
2024-2
SEMAGLUTIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
2.5 mg/1 mL
26436-5608-2
SEMAGLUTIDE
HUMAN COMPOUNDED DRUG
26436-5608
Hybrid Pharma
2024-2
SEMAGLUTIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
2.5 mg/1 mL
26436-5608-4
SEMAGLUTIDE
HUMAN COMPOUNDED DRUG
26436-5608
Hybrid Pharma
2024-2
SEMAGLUTIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
2.5 mg/1 mL
26436-5608-1
TESTOSTERONE 20%
HUMAN COMPOUNDED DRUG
26436-5605
Hybrid Pharma
2024-2
TESTOSTERONE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
200 mg/1 g
26436-5605-3
TESTOSTERONE
HUMAN COMPOUNDED DRUG
26436-5616
Hybrid Pharma
2024-2
TESTOSTERONE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
1 mg/1 g
26436-5616-3
Estradiol 1mg/gm
HUMAN COMPOUNDED DRUG
26436-5619
Hybrid Pharma
2024-2
ESTRADIOL
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
1 mg/1 g
26436-5619-3
Naltrexone HCL 6mg
HUMAN COMPOUNDED DRUG
26436-5633
Hybrid Pharma
2024-2
NALTREXONE HYDROCHLORIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
6 mg
26436-5633-1
ARGININE HCL 100MG/ML
HUMAN COMPOUNDED DRUG
26436-6002
Hybrid Pharma
2024-2
ARGININE HYDROCHLORIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
100 mg/1 mL
26436-6002-1
Phenylephrine HCl
HUMAN COMPOUNDED DRUG
71266-9010
Fagron Compounding Services LLC dba Fagron Sterile Services LLC dba JCB Laboratories
2024-2
PHENYLEPHRINE HYDROCHLORIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
.1 mg/1 mL
71266-9010-2
Succinylcholine Chloride
HUMAN COMPOUNDED DRUG
71266-9684
Fagron Compounding Services LLC dba Fagron Sterile Services LLC dba JCB Laboratories
2024-2
SUCCINYLCHOLINE CHLORIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
20 mg/1 mL
71266-9684-5
Neostigmine Methylsulfate
HUMAN COMPOUNDED DRUG
71266-2003
Fagron Compounding Services LLC dba Fagron Sterile Services LLC dba JCB Laboratories
2024-2
NEOSTIGMINE METHYLSULFATE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
1 mg/1 mL
71266-2003-9
网站地图 - 网站开发 - 网站简介 - 会员服务 - 法律声明 - 联系我们 - 药品招商频道 - 药品信息排行 - 2018年版国家基本药物目录 - 意见反馈
免责声明：以上所展示的信息由企业自行提供，内容的真实性、准确性和合法性由发布企业负责，医药网对此不承担任何责任。
相关链接：医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究　　客服热线：0575-83552251 / 13754370441  QQ客服：药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证：浙B2-20220931　互联网药品信息服务资格证书编号：(浙)-经营性2023-0215　浙公网安备:330683240604819103159
　医药代理商群１：药药网药品采购交流医药代理商群２：药药网药品采购交流2医药代理商群３：药药网药品采购交流3